Movatterモバイル変換

[0]ホーム

Пређи на садржај

LPAR2

Уреди везе

С Википедије, слободне енциклопедије

Receptor lizofosfatidne kiseline 2

Identifikatori

Simboli

LPAR2; EDG-4; EDG4; LPA-2; LPA2

Vanjski ID

OMIM: 605110MGI: 1858422HomoloGene: 3465IUPHAR:LPA₂GeneCards:LPAR2 Gene

Ontologija gena
Molekularna funkcija	•vezivanje G-protein alfa podjedinice •aktivnost G-protein spregnutog receptora •proteinsko vezivanje •vezivanje PDZ domena •veivanje LIM domena
Celularna komponenta	•citoplazma •ćelijska membrana •integralno sa ćelijskom membranom •ćelijska površina
Biološki proces	•activacija MAPK aktivnosti •signalni put G-protein spregnutog receptora •aktivacija fosfolipaze C •povišenje koncentracije citozolnih jona kalcijuma

Pregled RNK izražavanja

podaci

Ortolozi

Vrsta

Čovek

Miš

RefSeq (mRNA)

RefSeq (protein)

Lokacija (UCSC)

Chr 19:
19.73 - 19.74 Mb

Chr 8:
72.35 - 72.36 Mb

PubMed pretraga

[1]

[2]

Receptor lizofosfatidne kiseline 2 (LPA₂) jeprotein koji je kod ljudi kodiranLPAR2genom.^[1]^[2]^[3] LPA₂ jeG protein spregnuti receptor za koji se vezuje lipidni signalni molekullizofosfatidna kiselina (LPA).^[4]

Funkcija

[уреди |уреди извор]

Ovaj protein je član familije I G protein spregnutih receptora, kao i EDG familije. Ovaj protein funkcioniše kao receptor lizofosfatidne kiseline i doprinosi mobilizaciji Ca²⁺. To je kritični ćelijski respons na LPA, putem asocijacije sa Gi i Gq proteinima.^[1]

Interakcije

[уреди |уреди извор]

LPAR2 formirainterakcije saTRIP6.^[5]

Reference

[уреди |уреди извор]

^^а ^б„Entrez Gene: LPAR2 Lysophosphatidic acid receptor 2”.
^An S, Bleu T, Hallmark OG, Goetzl EJ (1998). „Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid”.J. Biol. Chem.273 (14): 7906—10.PMID 9525886.doi:10.1074/jbc.273.14.7906.
^An S, Bleu T, Zheng Y, Goetzl EJ (1998). „Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization”.Mol. Pharmacol.54 (5): 881—8.PMID 9804623.
^Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, Chun J (2010). „LPA Receptors: Subtypes and Biological Actions”.Annual Review of Pharmacology and Toxicology.50 (1): 157—186.PMID 20055701.doi:10.1146/annurev.pharmtox.010909.105753.
^Xu, Jun; Lai Yun-Ju; Lin Weei-Chin; Lin Fang-Tsyr (2004). „TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor”.J. Biol. Chem. United States.279 (11): 10459—68.ISSN 0021-9258.PMID 14688263.doi:10.1074/jbc.M311891200.

Literatura

[уреди |уреди извор]

Spiegel, S. (2000). „Sphingosine 1-phosphate: a ligand for the EDG-1 family of G-protein-coupled receptors.”.Ann. N. Y. Acad. Sci.905: 54—60.PMID 10818441.doi:10.1111/j.1749-6632.2000.tb06537.x.
Contos JJ, Ishii I, Chun J (2001). „Lysophosphatidic acid receptors.”.Mol. Pharmacol.58 (6): 1188—96.PMID 11093753.
Goetzl, E. J.; Dolezalova, H.; Y, Kong; et al. (1999). „Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer.”.Cancer Res.59 (20): 5370—5.PMID 10537322.
Contos JJ, Chun J (2000). „Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a previously characterized cDNA.”.Genomics.64 (2): 155—69.PMID 10729222.doi:10.1006/geno.2000.6122.
Bandoh, K.; J, Aoki; Taira, A.; et al. (2000). „Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors.”.FEBS Lett.478 (1–2): 159—65.PMID 10922489.doi:10.1016/S0014-5793(00)01827-5.
Young, K. W.; Bootman, M. D.; Channing, D. R.; et al. (2001). „Lysophosphatidic acid-induced Ca2+ mobilization requires intracellular sphingosine 1-phosphate production. Potential involvement of endogenous EDG-4 receptors.”.J. Biol. Chem.275 (49): 38532—9.PMID 10954727.doi:10.1074/jbc.M006631200.
Zheng Y, Voice JK, Kong Y, Goetzl EJ (2001). „Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes.”.FASEB J.14 (15): 2387—9.PMID 11024010.doi:10.1096/fj.00-0492fje.
Hama, K.; K, Bandoh; Kakehi, Y.; et al. (2002). „Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors.”.FEBS Lett.523 (1–3): 187—92.PMID 12123830.doi:10.1016/S0014-5793(02)02976-9.
Strausberg, R. L.; Feingold, E. A.; Grouse, L. H.; et al. (2003).„Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.”.Proc. Natl. Acad. Sci. U.S.A.99 (26): 16899—903.PMC 139241 .PMID 12477932.doi:10.1073/pnas.242603899.
Fujita, T.; S, Miyamoto; Onoyama, I.; et al. (2003). „Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer.”.Cancer Lett.192 (2): 161—9.PMID 12668280.doi:10.1016/S0304-3835(02)00713-9.
Hu YL, Albanese C, Pestell RG, Jaffe RB (2003). „Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells.”.J. Natl. Cancer Inst.95 (10): 733—40.PMID 12759391.doi:10.1093/jnci/95.10.733.
Xu J, Lai YJ, Lin WC, Lin FT (2004). „TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor.”.J. Biol. Chem.279 (11): 10459—68.PMID 14688263.doi:10.1074/jbc.M311891200.
Ota, T.; Y, Suzuki; Nishikawa, T.; et al. (2004). „Complete sequencing and characterization of 21,243 full-length human cDNAs.”.Nat. Genet.36 (1): 40—5.PMID 14702039.doi:10.1038/ng1285.
Grimwood, J.; Gordon, L. A.; Olsen, A.; et al. (2004). „The DNA sequence and biology of human chromosome 19.”.Nature.428 (6982): 529—35.PMID 15057824.doi:10.1038/nature02399.
Oh, Y. S.; Jo, N. W.; Choi, J. W.; et al. (2004).„NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-beta3 activation.”.Mol. Cell. Biol.24 (11): 5069—79.PMC 416407 .PMID 15143197.doi:10.1128/MCB.24.11.5069-5079.2004.
Gerhard, D. S.; Wagner, L.; Feingold, E. A.; et al. (2004).„The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).”.Genome Res.14 (10B): 2121—7.PMC 528928 .PMID 15489334.doi:10.1101/gr.2596504.

Vidi još

[уреди |уреди извор]

Lizofosfolipidni receptor

Spoljašnje veze

[уреди |уреди извор]

„Lysophospholipid Receptors: LPA₂”.IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Архивирано изоригинала 03. 03. 2016. г.
Lysophospholipid+receptors наUS National Library of Medicine Medical Subject Headings (MeSH)

Transmembranski receptor:receptori spregnuti s G proteinom

Klasa A:Rodopsinu slični

Neurotransmiter

Adrenergički	α1 (A,B,D) • α2 (A,B,C) • β1 • β2 • β3
Purinski	Adenozinski (A1,A2A,A2B,A3) • P2Y (1,2,4,5,6,8,9,10,11,12,13,14)
Serotoninski	(svi osim 5-HT3)5-HT1 (A,B,D,E,F) • 5-HT2 (A,B,C) • 5-HT (4,5A,6,7)
Drugi	Acetilholin (M1,M2,M3,M4,M5) • Dopamin (D1,D2,D3,D4,D5) • Histamin (H1,H2,H3,H4) • Melatonin (1A,1B,1C) • TAAR (1,2,3,5,6,8,9)

Metaboliti i
signalni molekuli

Eikozanoidni	CysLT (1,2) • LTB4 (1,2) • FPRL1 • OXE • Prostaglandin (DP (1,2),EP (1,2,3,4),FP) • Prostaciklin • Tromboksan
Drugi	Žučna kiselina • Kanabinoidni (CB1,CB2,GPR (18,55,119)) • EBI2 • Estrogen • Slobodna masna kiselina (1,2,3,4) • Laktat • Lizofosfatidna kiselina (1,2,3,4,5,6) • Lizofosfolipid (1,2,3,4,5,6,7,8) • Niacin (1,2) • Oksoglutarat • PAF • Sfingozin-1-fosfat (1,2,3,4,5) • Sukcinat

Peptid

Neuropeptidni

B/W (1,2) • FF (1,2) • S • Y (1,2,4,5) • Neuromedin (B,U (1,2)) • Neurotenzin (1,2)

Drugi

Anafilatoksin (C3a,C5a) • Angiotenzin (1,2) • Apelin • Bombezin (BRS3,GRPR,NMBR) • Bradikinin (B1,B2) • Hemokin • Holecistokinin (A,B) • Endotelin (A,B) • Formil peptid (1,2,3) • FSH • Galanin (1,2,3) • GHB receptor • Gonadotropin-oslobađajući hormon (1,2) • Grelin • Kispeptin • Luteinizirajući hormon/horiogonadotropin • MAS (1,1L,D,E,F,G,X1,X2,X3,X4) • Melanokortin (1,2,3,4,5) • MCHR (1,2) • Motilin • Opioidni (δ,κ,μ,Nociceptin &ζ, ali neσ) • Oreksin (1,2) • Oksitocin • Prokineticin (1,2) • Prolaktin-oslobađajući peptid • Relaksin (1,2,3,4) • Somatostatin (1,2,3,4,5) • Tahikinin (1,2,3) • Tirotropin • Tirotropin-oslobađajući hormon • Urotenzin-II • Vazopresin (1A,1B,2)

Razno

Orfan	GPR (1,3,4,6,12,15,17,18,19,20,21,22,23,25,26,27,31,32,33,34,35,37,39,42,44,45,50,52,55,61,62,63,65,68,75,77,78,81,82,83,84,85,87,88,92,101,103,109A,109B,119,120,132,135,137B,139,141,142,146,148,149,150,151,152,153,160,161,162,171,173,174,176,177,182,183)
Drugi	Adrenomedulin • Mirisni • Opsin (3,4,5,1LW,1MW,1SW,RGR,RRH) • Proteazom-aktivirani (1,2,3,4) • SREB (1,2,3)

Klasa B:Sekretinu slični

Orfan	GPR (56,64,97,98,110,111,112,113,114,115,116,123,124,125,126,128,133,143,144,155,157)
Drugi	Moždano specifični angiogenezni inhibitor (1,2,3) • Kadherin (1,2,3) • Kalcitonin • CALCRL • CD97 • Kortikotropin-oslobađajući hormon (1,2) • EMR (1,2,3) • Glukagon (GR,GIPR,GLP1R,GLP2R) • Hormon rasta • PACAPR1 • GPR • Latrofilin (1,2,3,ELTD1) • Metuzalemski protein • Paratiroidni hormon (1,2) • Sekretin • Vazoaktivni intestinalni peptid (1,2)

Klasa C:Metabotropni
glutamat /feromon

Ukus	TAS1R (1,2,3) • TAS2R (1,3,4,5,8,9,10,12,13,14,16,19,20,30,31,38,39,40,41,42,43,45,46,50)
Drugi	Kalcijum-detektujući receptor • GABA B (1,2) • Glutamatni receptor (Metabotropni glutamat (1,2,3,4,5,6,7,8)) • GPRC6A • GPR (156,158,179) • RAIG (1,2,3,4) • VNR (1,2,3,5)

Klasa F:
Frizzled /Zaglađeni

Uvojiti	Frizzled (1,2,3,4,5,6,7,8,9,10)
Zaglađeni	Zaglađeni

Преузето из „https://sr.wikipedia.org/w/index.php?title=LPAR2&oldid=29209938”

Категорије:

Сакривене категорије:

[8]ページ先頭